[1] |
Gripp KW, Lin AE. Costello syndrome [M/OL]// Pagon RA, Adam MP, Ardinger HH, et al. GeneReviews. [Internet] (2012⁃01⁃12)[2017⁃05⁃26]. Seattle (WA): University of Washington, 1993⁃2017. https://www.ncbi.nlm.nih.gov/books/NBK1507/.
|
[2] |
Sol⁃Church K, Stabley DL, Demmer LA, et al. Male⁃to⁃male transmission of Costello syndrome: G12S HRAS germline mutation inherited from a father with somatic mosaicism[J]. Am J Med Genet A, 2009, 149A(3): 315⁃321. DOI: 10.1002/ajmg.a. 32639.
|
[3] |
张寒冰, 邱正庆, 王薇, 等. 国内首例Costello综合征患儿HRAS基因突变分析[J]. 基础医学与临床, 2010, 30(12): 1274⁃1277.
|
[4] |
Kerr B, Delrue MA, Sigaudy S, et al. Genotype⁃phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases[J]. J Med Genet, 2006, 43(5): 401⁃405. DOI: 10.1136/jmg.2005.040352.
|
[5] |
Hartung AM, Swensen J, Uriz IE, et al. The splicing efficiency of activating HRAS mutations can determine Costello syndrome phenotype and frequency in cancer[J/OL]. PLoS Genet, 2016, 12(5): e1006039 [2017⁃05⁃26]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873146/. DOI: 10.1371/journal.pgen.1006039.
|
[6] |
Siegel DH, Mann JA, Krol AL, et al. Dermatological phenotype in Costello syndrome: consequences of Ras dysregulation in development[J]. Br J Dermatol, 2012, 166(3): 601⁃607. DOI: 10.1111/j.1365⁃2133.2011.10744.x.
|
[7] |
Lo IF, Brewer C, Shannon N, et al. Severe neonatal manifestations of Costello syndrome[J]. J Med Genet, 2008, 45(3): 167⁃171. DOI: 10.1136/jmg.2007.054411.
|
[8] |
Hinek A, Smith AC, Ctiongco EM, et al. Decreased elastin deposition and high proliferation of fibroblasts from Costello syndrome are related to functional deficiency in the 67⁃kD elastin⁃binding protein[J]. Am J Hum Genet, 2000, 66(3): 859⁃872. DOI: 10.1086/302829.
|
[9] |
Lin AE, Alexander ME, Colan SD, et al. Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: a Ras/MAPK pathway syndrome[J]. Am J Med Genet A, 2011, 155A(3): 486⁃507. DOI: 10.1002/ajmg.a.33857.
|
[10] |
Gripp KW, Lin AE. Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations[J]. Genet Med, 2012, 14(3): 285⁃292. DOI: 10.1038/gim.0b013e31822dd91f.
|
[11] |
Kerr B, Delrue MA, Sigaudy S, et al. Genotype⁃phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases[J]. J Med Genet, 2006, 43(5): 401⁃405. DOI: 10.1136/jmg.2005.040352.
|
[12] |
Lorenz S, Petersen C, Kordaß U, et al. Two cases with severe lethal course of Costello syndrome associated with HRAS p.G12C and p.G12D[J]. Eur J Med Genet, 2012, 55(11): 615⁃619. DOI: 10.1016/j.ejmg.2012.07.007.
|
[13] |
Rauen KA. The RASopathies[J]. Annu Rev Genomics Hum Genet, 2013, 14: 355⁃369. DOI: 10.1146/annurev⁃genom⁃091212⁃153523.
|
[14] |
Myers A, Bernstein JA, Brennan ML, et al. Perinatal features of the RASopathies: Noonan syndrome, cardiofaciocutaneous syndrome and Costello syndrome[J]. Am J Med Genet A, 2014, 164A(11): 2814⁃2821. DOI: 10.1002/ajmg.a.36737.
|